| Full text | |
| Author(s): |
Lorena Blau
;
Renato Farina Menegon
;
Man Chin Chung
Total Authors: 3
|
| Document type: | Journal article |
| Source: | Química Nova; v. 29, n. 6, p. 1307-1317, Dez. 2006. |
| Abstract | |
Strategies that promote selective activation of prodrugs by enzymes can be divided into two major classes: 1) deliver of a monoclonal antibody-enzyme immunoconjugate that can recognize a specific antigen and promote the prodrug to a citotoxic drug, with a high selectivity for the target cells, and 2) selective gene delivery encoding an enzyme that can promote the prodrug to a citotoxic drug for the target cells. In this article are discussed ADEPT (antibody-directed enzyme prodrug therapy), GDEPT (gene-directed enzyme prodrug therapy), VDEPT (virus-directed enzyme prodrug therapy), GPAT (genetic prodrug activation therapy) and PDEPT (polymer-directed enzyme prodrug therapy) approaches, their clinical trials, advantages, disadvantages and perspectives. (AU) | |
| FAPESP's process: | 01/01192-3 - Potential antitripanosomal derived from nitro-heterocyclic compounds |
| Grantee: | Elizabeth Igne Ferreira |
| Support type: | Research Projects - Thematic Grants |